Assessing prognosis by quantifying FcγRIIa on fixed platelets

Area of Science:

• Immunology
• Hematology
• Biotechnology

Background:

• FcγRIIa amplifies platelet activation, and elevated levels indicate higher cardiovascular event risk.
• Accurate quantification of FcγRIIa on platelets is crucial for risk stratification.

Purpose of the Study:

• To report the accuracy and precision of a modified test for quantifying FcγRIIa on fixed platelets (pFCG test).

Main Methods:

• Developed a novel antibody clone (5G1) targeting formaldehyde-treated FcγRIIa.
• Evaluated test accuracy and precision using biologic platelets and engineered synthetic cells.
• Assessed intra-assay and interassay coefficients of variation (CV).

Main Results:

• The modified pFCG test on fixed platelets detected ~300 molecules more FcγRIIa compared to non-fixed platelets.
• Intra-assay CV was 2.1% ± 0.1% for biologic specimens.
• Interassay CVs were 4.5% ± 1% (intraday) and 6.5% ± 0.4% (interday up to 5 days).
• Synthetic cells showed accuracy, linearity (R²=0.984), and interassay CVs of 2% ± 0.6% (intraday) and 9.9% ± 2.1% (interday).

Conclusions:

• Modification of the pFCG test for fixed platelets enables accurate FcγRIIa quantification.
• The modified test demonstrates high precision, suitable for clinical applications.
• Improved FcγRIIa measurement aids in identifying patients at risk for cardiovascular events.